Skip to main content Skip to navigation
FITC Mouse Anti-Human FMC7
Product Details
Down Arrow Up Arrow


BD™
Human
Mouse IgM, κ
Human B-lymphoblastoid cell line HRIK
Flow cytometry
25 μg/mL
20 μL
931
Phosphate buffered saline with gelatin and 0.1% sodium azide.
RUO (GMP)


Preparation And Storage

Store vials at 2°C to 8°C. Conjugated forms should not be frozen and should be protected from exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

340919 Rev. 1
Antibody Details
Down Arrow Up Arrow
FMC7

Clone FMC7 is derived from the fusion of mouse P3-NS1-1-AG4-1 myeloma cells with spleen cells from BALB/c mice immunized with human B-lymphoblastoid cell line HRIK.

FMC7 recognizes a 105-kDa membrane glycoprotein expressed on a subset of B lymphocytes.

340919 Rev. 1
Format Details
Down Arrow Up Arrow
FITC
Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
FITC
Blue 488 nm
494 nm
518 nm
340919 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (10)

  1. Bloem AC, Chand MA, Dollekamp I, Rijkers GT. Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7. J Immunol. 1988; 140:768-773. (Biology).
  2. Brooks DA, Beckman IG, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids, IV, A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol. 1981; 126:1373-1377. (Biology).
  3. Catovsky D, Brooks CD, Bradley J, Zola H. Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood. 1981; 58:406-408. (Biology).
  4. Ferro LM, Zola H. Modulation of expression of the antigen identified by FMC7 upon human Blymphocyte activation: evidence for differences between activation in vivo and in vitro. Immunology. 1990; 69:373-378. (Biology).
  5. Geisler CH, Larsen JK, E HN, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991; 78:1795-1802. (Biology).
  6. Huh YO, Pugh WC, Kantarjian HM, et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol. 1994; 101:283-289. (Biology).
  7. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol . 1996; 105:451-457. (Biology).
  8. Rijkers GT, Dollekamp I, Zegers BJM. Evidence that FMC7 is a human B cell differentiation antigen. Immunol Lett. 1990; 24:261-264. (Biology).
  9. Staal F, Rozemuller E, Gmelig Meyling FHJ, Bloem AC. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:139-140.
  10. Zola H, Neoh SH, Potter A, Melo JV, De Oliveria MSP, Catovsky D. Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. Disease Markers. 1987; 5:227-235. (Biology).
View All (10) View Less
340919 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 

 

Although not required, these products are manufactured in accordance with Good Manufacturing Practices.